ArticleCell metabolism2023
Immunoediting instructs tumor metabolic reprogramming to support immune evasion.
Open access · greenAbstract read
In one paragraph
Article in Cell metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
23.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 96 citations in OpenAlex.
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- PET/CT imaging for assessment of tumor immunotherapy response: a new perspective on tumor metabolic reprogramming and immune escape.La Radiologia medica · 2026Review
- A Self-Immunoregulatory Nanosensitizer for Sonodynamic Cancer Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Pestivirus bovine viral diarrhea virus infection induces ROS-HIF-1a axis-driven glycolytic reprogramming, which increases viral replication by impairing RIG-I-dependent type I interferon response.Journal of virology · 2026Article
- Bi-directional regulation between NAD/NAMPT and IFN-γ/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- From guardians to traitors: molecular mechanisms of tumor-induced T cell betrayal.Molecular cancer · 2026Review
- Article
- SNHG12 drives gastric cancer progression by activating the Wnt/β-catenin-mediated serine synthesis pathway.Journal of translational medicine · 2026Article
- Tumor-targeted aptamer-conjugated engineered bacteria for CXCL9 cytokine delivery in non-small cell lung cancer immunotherapy.Journal of translational medicine · 2026Article
- Lytic IFNγ is stored in cytotoxic granules and coreleased with granzyme B to mediate cytotoxic T lymphocyte killing.Cellular & molecular immunology · 2026Article
- A photothermal immune hydrogel dressing for enhanced post-melanoma resection treatment.Journal of nanobiotechnology · 2026Article
- Transient hypoxia followed by progressive reoxygenation is required for muscle repair.EMBO reports · 2026Article
- A pan-cancer atlas of metabolic regulatory circuitries integrating multi-omic, immune, and clinical dimensions.Frontiers in molecular biosciences · 2026Article
- Metabolic reprogramming and immune evasion interaction in the tumor microenvironment promote tumor progression.Frontiers in oncology · 2026Review
- Regulating the regulators via targeting CD38 in the tumor microenvironment.Frontiers in immunology · 2026Review
- Tumor-immune metabolic tug-of-war: from immune escape to targeting metabolic rewiring in cancer therapy.Frontiers in cell and developmental biology · 2026Review
- Metabolic adaptations in cancer progression.Physiological reviews · 2026Review
- Spatiotemporal control of mitoribosome-mediated metabolic reprogramming in cancer: implications for heterogeneity and therapeutic targeting.Frontiers in cell and developmental biology · 2026Review
- STAT3 signaling in cancer: mechanisms and targeting therapeutic.Frontiers in immunology · 2026Review
- Interferon signaling pathways in health and disease.Molecular biomedicine · 2025Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
23 authors at 10 institutions in 6 countries.
Chin-Hsien TsaiDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute of Cancer Research, University of Lausanne, Lausanne, Switzerland; Graduate Institute of Life Sciences, National Defense Medical Center, Taipei City, Taiwan.
Yu-Ming ChuangDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute of Cancer Research, University of Lausanne, Lausanne, Switzerland.
Xiaoyun LiDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute of Cancer Research, University of Lausanne, Lausanne, Switzerland.
Yi-Ru YuDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute of Cancer Research, University of Lausanne, Lausanne, Switzerland.
Sheue-Fen TzengDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute of Cancer Research, University of Lausanne, Lausanne, Switzerland; Graduate Institute of Life Sciences, National Defense Medical Center, Taipei City, Taiwan.
Shao Thing TeohDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA.
Katherine E LindbladDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mario Di MatteoLaboratory of Tumor Inflammation and angiogenesis, Vesalius Research Center, VIB, Leuven, Belgium; Laboratory of Tumor Inflammation and angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.
Wan-Chen ChengDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute of Cancer Research, University of Lausanne, Lausanne, Switzerland.
Pei-Chun HsuehDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute of Cancer Research, University of Lausanne, Lausanne, Switzerland.
Kung-Chi KaoDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute of Cancer Research, University of Lausanne, Lausanne, Switzerland.
Hana ImrichovaCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Wien, Austria.
Likun DuanDepartment of Molecular and Structural Biochemistry, North Carolina State University, Raleigh, NC, USA.
Hector Gallart-AyalaMetabolomics Platform, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Pei-Wen HsiaoAgricultural Biotechnology Research Center, Academia Sinica, Taipei City, Taiwan.
Massimiliano MazzoneLaboratory of Tumor Inflammation and angiogenesis, Vesalius Research Center, VIB, Leuven, Belgium; Laboratory of Tumor Inflammation and angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.
Julijana IvanesevicCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Wien, Austria.
Xiaojing LiuDepartment of Molecular and Structural Biochemistry, North Carolina State University, Raleigh, NC, USA.
Karin E de VisserDivision of Tumor Biology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Amaia LujambioDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sophia Y LuntDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA; Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, MI, USA.
Susan M KaechNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.
Ping-Chih HoDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute of Cancer Research, University of Lausanne, Lausanne, Switzerland. Electronic address: ping-chih.ho@unil.ch.
Ludwig Cancer Research · CHAustrian Academy of Sciences · ATIcahn School of Medicine at Mount Sinai · USMichigan State University · USNorth Carolina State University · USVIB-KU Leuven Center for Cancer Biology · BEAgricultural Biotechnology Research Center, Academia Sinica · TWSalk Institute for Biological Studies · USThe Netherlands Cancer Institute · NLUniversity of Lausanne · CH
Funding
TRAINING PROGRAM IN CANCER THERAPYT32CA078207 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI James J Manfredi · 1999 to 2026
$11.6M(PQ1) Lipid Metabolism, Inflammation, and T cell Dysfunction in HIV-associated CancerR01CA206483 · NCI · YALE UNIVERSITY · PI EMU, BRINDA, KAECH, SUSAN M · 2017 to 2021
$3.2MTumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinomaR37CA230636 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LUJAMBIO, AMAIA · 2018 to 2024
$2.7MExamining PHGDH-mediated activation of sialic acid metabolism to drive triple-negative breast cancer metastasisR01CA270136 · NCI · MICHIGAN STATE UNIVERSITY · PI Sophia Lunt · 2022 to 2026
$2.0MNCI NIH HHS R01 CA206483NCI NIH HHS R01 CA270136NCI NIH HHS R37 CA230636NCI NIH HHS T32 CA078207
Abstract
Immunoediting sculpts immunogenicity and thwarts host anti-tumor responses in tumor cells during tumorigenesis; however, it remains unknown whether metabolic programming of tumor cells can be guided by immunosurveillance. Here, we report that T cell-mediated immunosurveillance in early-stage tumorigenesis instructs c-Myc upregulation and metabolic reprogramming in tumor cells. This previously unexplored tumor-immune interaction is controlled by non-canonical interferon gamma (IFNγ)-STAT3 signaling and supports tumor immune evasion. Our findings uncover that immunoediting instructs deregulated bioenergetic programs in tumor cells to empower them to disarm the T cell-mediated immunosurveillance by imposing metabolic tug-of-war between tumor and infiltrating T cells and forming the suppressive tumor microenvironment.
Indexed as
Immune EvasionNeoplasmsCarcinogenesisCell Transformation, NeoplasticHumansInterferon-gammaT-LymphocytesTumor MicroenvironmentInterferon-gammaIFNγimmunoeditingimmunosurveillanceMycSTAT3tumor immunology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.